This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): MAC-321, TL139
Description: MAC-321 is an analog of Taxotere (Docetaxel). Similar to Paclitaxel and Docetaxel, MAC-321 prevents cell divsion (mitosis) by disrupting the normal process of microtubule assembly and disassembly.
Microtubules are cylindrical structures that form the basis of the cellular skeleton and are essential to the reproduction, growth, and spread of tumor cells. Normally, as a part of the mitotic process, microtubules are reorganized to form a spindle. MAC-321 binds tubulin, promoting polymerization and preventing de-polymerization of microtubules, resulting in cell death.
Deal Structure: In October 2001, Taxolog entered into a major collaboration and license agreement involving FSU inventions with Wyeth Ayerst Laboratories. Under the agreement the two companies will collaboratively research novel compounds for use as potential anti-tumor agents that Wyeth will exclusively develop, manufacture and commercialize. Milataxel is included in this development agreement.
In 2006, Wyeth returned all rights of MAC-321 to Taxolog and is no longer involved in the development of the compound.
Additional information available to subscribers only: